MRD Archives - Geneseeq Technology Inc. | A Precision Oncology Company

August 26, 2026

Beyond Mutation-Only MRD: Making Better Use of ctDNA Data

July 14, 2026

Geneseeq Canada Named First Genomic Testing Partner in UHN’s SHERLOCK Study

May 21, 2025

Geneseeq Showcases Cutting-Edge Liquid Biopsy Research Across Multiple Cancer Types at ASCO 2025

April 9, 2025

Geneseeq Technology Inc. to showcase seventeen studies at 2025 American Association for Cancer Research (AACR) annual meeting

March 6, 2024

Geneseeq to Showcase Twelve Studies at 2024 American Association for Cancer Research (AACR) Annual Meeting

May 16, 2023

Geneseeq published new research on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer

March 9, 2023

Geneseeq and Collaborators Initiate MOTION Study to Evaluate the Performance of Minimal Residual Disease Test SHIELDING™ in Early-stage Lung Cancer

January 24, 2023

Geneseeq receives CE Marks for MRD and MCED tests.

October 12, 2022

Interesting findings on ctDNA-based MRD detection in patients with resectable non-small cell lung cancer by Geneseeq

August 31, 2021

Geneseeq Study Evaluates ctDNA MRD to Predict Response to Therapy and Assess Prognosis in Locally Advanced Rectal Cancer